WallStSmart

Guardant Health Inc (GH)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 3816% more annual revenue ($46.34B vs $1.18B). TMO leads profitability with a 15.0% profit margin vs -38.3%. TMO earns a higher WallStSmart Score of 60/100 (C+).

GH

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.58

TMO

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GH.

TMOSignificantly Overvalued (-76.7%)

Margin of Safety

-76.7%

Fair Value

$345.06

Current Price

$609.82

$264.76 premium

UndervaluedFair: $345.06Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GH2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
44.3%10/10

Revenue surging 44.3% year-over-year

Debt/EquityHealth
-7.6110/10

Conservative balance sheet, low leverage

TMO2 strengths · Avg: 9.0/10
Market CapQuality
$225.48B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

GH4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-4584.0%2/10

ROE of -4584.0% — below average capital efficiency

Free Cash FlowQuality
$-69.54M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-1.582/10

Distress zone — elevated risk

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.804/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : GH

The strongest argument for GH centers on Revenue Growth, Debt/Equity. Revenue growth of 44.3% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : GH

The primary concerns for GH are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

GH profiles as a hypergrowth stock while TMO is a value play — different risk/reward profiles.

GH carries more volatility with a beta of 1.58 — expect wider price swings.

GH is growing revenue faster at 44.3% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (60/100 vs 31/100) and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Guardant Health Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?